Search for drugs:
Typing the drug name to query
AMIFAMPRIDINE PHOSPHATE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- The effect of FIRDAPSE on QTc interval prolongation was studied in a double blind, randomized, placebo and positive controlled study in 52 healthy individuals who are slow acetylators. At an exposure 2-fold the expected maximum therapeutic exposure of amifampridine, FIRDAPSE did not prolong QTc to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- N07XX05 - amifampridine phosphate
- N07XX - Other nervous system drugs
- N07X - OTHER NERVOUS SYSTEM DRUGS
- N07 - OTHER NERVOUS SYSTEM DRUGS
- N - NERVOUS SYSTEM
Active Ingredient:amifampridine phosphate
Active Ingredient UNII:8HF8FIN815
Drugbank ID:DB11640
PubChem Compound:N/ADIR Classification
CTD ID: D000077770
CAS Number:54-96-6
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
- 40.0 mg/day N07XX05
Chemical Structure: 
SMILE Code:
NC1=CC=NC=C1N
NC1=CC=NC=C1N
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.